Product for Licensing - 药时代DrugTimes

首页
药资讯
视频专区
精彩活动
BD投融资平台
药时代学苑
All English
联系我们

登录注册

Product for Licensing

Filter by Indication

Oncology
Immunology
CNS/Pain
Anti infection/viral
Digestion/Endocrinology/Metabolism

Small Molecule

A Potentially Best-in-Class (BIC) Pan-RAS (ON) Inhibitor with Superior PK Profile and Significant Pharmacological Efficacy

2025年8月4日 0
Pre-clinical

A Preclinical Menin-MLL Inhibitor for Acute Myeloid Leukemia (AML) Seeking Partners

2025年7月29日 0
Oncology

【pre-PCC】A Potential Best-in-Class CDK2 Inhibitor with Better Selectivity, Better Efficacy and Superior PK【Product for Licensing】

2025年6月17日 0
Product for Licensing

【Phase I】First-in-class Phase I Dual-target Oral Molecular Glue for Hematologic Malignancies with Broad-spectrum Activity and Better Safety Profile 【Product for Licensing】

2025年6月17日 0
Oncology

An innovative PET tracer for brain tumor diagnosis, with BIC potential

2024年12月23日 0
Oncology

A Highly Differentiated EGFR x HER2 Bispecific ADC for Targeted Therapy of Multiple Types of Solid Tumors 【Product for Licensing】

2024年11月12日 0

点击查看更多

Skin and Otolaryngology
Cardiovascular
Respiratory
Urology/Reproduction
Others

Product for Licensing

DrugTimes BD Project | A Anti-C3 Nanobody Indicated for Geographic Atrophy

2025年7月28日 0

点击查看更多

Filter by Stage

PCC
Pre-clinical
IND
Phase I
Phase II
Phase III
NDA
Approval

PCC

A Best-in-Class Oral Small-Molecule GLP-1 Receptor Agonist with Superior Weight Loss and Appetite Suppression Efficacy | PharmaTimes BD Opportunity

2025年8月19日 0
Product for Licensing

An asset similar to Roche’s trontinemab | DrugTimes BD Project

2025年7月31日 0
Product for Licensing

DrugTimes BD Project DTC-059 | Dual-Action FXl/FXla Inhibitor: A Low-Bleeding，Superior-Efficacy Antibody with Best-in-Class Potential

2025年7月29日 0
Oncology

【pre-PCC】A Potential Best-in-Class CDK2 Inhibitor with Better Selectivity, Better Efficacy and Superior PK【Product for Licensing】

2025年6月17日 0
Immunology

密码保护：A New Class of IRAK4 PROTAC with Best-in-Class Potential 【Product for Licensing】

2024年8月13日 0
Antibody

High Binding Affinities and Potent Anti-tumor Efficacy Nectin4-CD137 BsAb 【Product for Licensing】

2024年8月1日 0

点击查看更多

Filter by Modality

Small Molecule
Peptide
Antibody
ADC/XDC
Protein
Protac
CGT
Vaccine
Others

PCC

A Best-in-Class Oral Small-Molecule GLP-1 Receptor Agonist with Superior Weight Loss and Appetite Suppression Efficacy | PharmaTimes BD Opportunity

2025年8月19日 0
Small Molecule

A Potentially Best-in-Class (BIC) Pan-RAS (ON) Inhibitor with Superior PK Profile and Significant Pharmacological Efficacy

2025年8月4日 0
Pre-clinical

A Preclinical Menin-MLL Inhibitor for Acute Myeloid Leukemia (AML) Seeking Partners

2025年7月29日 0
CNS/Pain

【IND enabling】TYK2/JAK1 Dual Inhibitor Breaks New Ground in CNS Drug Development【Product for Licensing】

2025年7月15日 0
Product for Licensing

【Phase I】First-in-class Phase I Dual-target Oral Molecular Glue for Hematologic Malignancies with Broad-spectrum Activity and Better Safety Profile 【Product for Licensing】

2025年6月17日 0
CNS/Pain

Brain penetrating JAK1/TYK2 inhibitors for inflammation, autoimmune and CNS diseases

2024年12月23日 0

点击查看更多

TOP VIEWS

62.2K

【pre-PCC】A Potential Best-in-Class CDK2 Inhibitor with Better Selectivity, Better Efficacy and Superior PK【Product for Licensing】
【IND enabling】Once daily oral brain-penetrant dual JAK1/TYK2 inhibitor with better efficacy and safety

30.5K
DLL3 ADC！Two >1B licensing deals by Hengrui/IDEAYA Bio and Innovent Bio/Roche in just 4 days 【Product for Licensing】

22.8K
T-cell engager (TCE), bispecific, trispecific, and multispecific products are available 【Product for Licensing】

21.8K
A long-acting anti-TL1A mAb with best-in-class potential

15.9K

药资讯
精彩活动
BD投融资平台
药时代学苑
联系我们
免责声明 Disclaimer

Copyright Reserved © 药时代 DRUGTIMES 版权所有请勿转载

沪ICP备17025211号-1

本站部分文字及图片来源于网络，如侵犯到您的权益，请及时告知并联系 contact@drugtimes.cn，本站将及时处理或撤换，特此声明。

公众号

分享本页

返回顶部

BD